Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] – Therapeutics [E02]
The Cardiology Department at Nosokomeio Paidon I Agia Sofia is advancing novel diagnostic tools and therapeutic devices to improve patient monitoring and treatment delivery.
- Development of pediatric pharmacokinetic profiling for targeted therapies
- Implementation of advanced imaging for early detection of cardiac anomalies
- Evaluation of new device-based drug delivery systems in children
These efforts aim to refine precision medicine approaches across multiple disease areas.
Diseases [C] – Bacterial Infections and Mycoses [C01]
Clinical studies focus on complicated urinary tract infections and acute pyelonephritis in pediatric patients, testing newer antimicrobial regimens.
- Assessment of meropenem‑vaborbactam safety in children
- Comparison of treatment durations for acute pyelonephritis
- Exploration of resistance patterns to guide therapy
The goal is to enhance outcomes and reduce recurrence of severe bacterial infections.
Diseases [C] – Cardiovascular Diseases [C14]
Research targets heart failure due to left ventricular systolic dysfunction and familial hypercholesterolemia, evaluating novel agents and combination therapies.
- Long‑term safety of finerenone added to ACE inhibitors
- Impact on proteinuria and NT‑proBNP levels
- LDL‑C reduction with inclisiran in heterozygous familial hypercholesterolemia
These trials seek to improve cardiac function and reduce cardiovascular risk in children and adolescents.
Diseases [C] – Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Studies address growth disorders such as Turner syndrome, Noonan syndrome, and short stature, comparing growth hormone regimens.
- Weekly somapacitan versus daily Norditropin® effectiveness
- Height velocity outcomes across different growth indications
- Safety monitoring of long‑term hormone therapy
The aim is to support optimal growth trajectories in affected children.
Diseases [C] – Digestive System Diseases [C06]
The site conducts trials on inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, testing biologics and small molecules.
- Vedolizumab maintenance therapy efficacy
- Upadacitinib for clinical remission and endoscopic response
- Evaluation of mucosal healing with novel agents
These investigations aim to achieve durable remission and improve quality of life for pediatric patients.
Diseases [C] – Hemic and Lymphatic Diseases [C15]
Ongoing research evaluates treatments for hemophilia and thalassemia, focusing on prophylaxis and transfusion reduction.
- Concizumab prophylaxis effectiveness in hemophilia A/B with inhibitors
- SP‑420 dose‑response in transfusion‑dependent α/β‑thalassemia
- Mitapivat impact on anemia in non‑transfusion‑dependent thalassemia
The objective is to lessen bleeding episodes and transfusion burden while enhancing patient safety.
Diseases [C] – Hormonal diseases [C19]
Clinical trials aim to improve management of congenital adrenal hyperplasia and related endocrine disorders.
- Crinecerfont efficacy in reducing adrenal steroid levels
- Pharmacokinetic profiling of new hormone modulators
- Safety monitoring of long‑term endocrine therapy
These studies seek to provide better hormonal control and reduce disease complications.
Diseases [C] – Immune System Diseases [C20]
Investigations focus on autoimmune conditions such as Behçet’s disease and juvenile idiopathic arthritis, testing targeted immunomodulators.
- Apremilast long‑term safety in Behçet’s oral ulcers
- Sarilumab dosing for systemic juvenile idiopathic arthritis
- Filgotinib efficacy in polyarticular‑course juvenile idiopathic arthritis
The goal is to control inflammation, reduce flare frequency, and improve functional outcomes.
Diseases [C] – Musculoskeletal Diseases [C05]
Trials target muscular dystrophies and related disorders, evaluating gene‑based and anti‑inflammatory therapies.
- Vamorolone safety regarding vertebral fractures in Duchenne muscular dystrophy
- Viltolarsen intravenous dosing in boys with DMD
- Assessing functional improvement with novel anti‑fibrotic agents
These efforts aim to preserve muscle strength and delay disease progression.
Diseases [C] – Neoplasms [C04]
The department participates in pediatric oncology studies for neuroblastoma, ependymoma, and rhabdomyosarcoma, exploring intensified chemotherapy and immunotherapy.
- High‑dose chemotherapy versus tandem regimens in high‑risk neuroblastoma
- CAR‑T cell therapy safety and efficacy in hematologic malignancies
- Targeted RAF inhibition in low‑grade glioma
Objectives include improving event‑free survival and reducing late sequelae.
Diseases [C] – Nutritional and Metabolic Diseases [C18]
Research addresses iron overload and metabolic complications in thalassemia and sickle cell disease, testing chelation and metabolic modulators.
- REGN7999 subcutaneous dosing for iron overload reduction
- Etavopivat efficacy in sickle cell disease anemia management
- Rilzabrutinib prevention of vaso‑occlusive crises
The aim is to improve organ health and reduce disease‑related complications.
Diseases [C] – Pathological Conditions, Signs and Symptoms [C23]
Studies evaluate biomarkers and clinical signs such as proteinuria and renal dysfunction in chronic kidney disease.
- Finerenone impact on urine protein excretion
- Long‑term safety of finerenone combined with ACEI/ARB
- Assessment of renal outcomes in pediatric heart failure patients
These trials seek to mitigate renal injury and enhance overall patient prognosis.
